Subscribe

Cervical Cancer

Landoni Trial: Radical Surgery versus Radiotherapy for Stage Ib-IIa Cervical Cancer

There is no clear treatment of choice for early-stage cervical carcinoma in terms of overall or disease-free survival. Treatment should be tailored to individual patient factors such as menopausal status, age, medical conditions, histological type, and cervical diameter to achieve the best outcomes

Early Stage Cervical Cancer

CONCERV Trial

Conservative surgery is feasible for select patients with early-stage, low-risk cervical cancer

SENTIREC: SLND in Cervical Cancer Study from Denmark

SENTICOL 2: Quality of Life After Sentinel Lymph Node Dissection in Cervical Cancer

SENTICOL 1: Sentinel LND in Cervical Cancer

CheckMate 358: Nivolumab with or without Ipilimumab in Recurrent/Metastatic Cervical Cancer

Nivolumab alone or in combination with ipilimumab shows promise in recurrent or metastatic cervical cancer, with significant objective response rates and manageable safety profiles.

KEYNOTE A18: Pembrolizumab Plus Chemoradiotherapy for High-Risk Locally Advanced Cervical Cancer

Pembrolizumab combined with chemoradiotherapy and then continued post-chemoradiotherapy demonstrates significant improvements in progression-free survival and OS compared to chemoradiotherapy alone

CALLA: Durvalumab versus Placebo with Chemoradiotherapy for Locally Advanced Cervical Cancer

Durvalumab concurrent with chemoradiotherapy was well tolerated but did not significantly improve progression-free survival compared to placebo in a biomarker-unselected all-comers population for locally advanced cervical cancer

SHAPE: Simple vs. Radical Hysterectomy for Low-Risk Early-Stage Cervical Cancer

Simple hysterectomy is not inferior to radical hysterectomy in terms of the 3-year incidence of pelvic recurrence and presents a lower risk of urinary complications.